HIV infections Trials in Sankt Gallen, Switzerland
Conditions / HIV infections / Sankt Gallen, Switzerland
HIV infections has been the subject of sustained clinical investigation across multiple research sites.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01850212 | A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects | COMPLETED | — |
| NCT00561925 | VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients | COMPLETED | PHASE3 |
| NCT00245739 | TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens. | APPROVED_FOR_MARKETING | — |
| NCT00146328 | Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects | COMPLETED | PHASE2/PHASE3 |
| NCT00458302 | Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir | COMPLETED | PHASE3 |
| NCT00389207 | Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults | COMPLETED | PHASE3 |
| NCT00098722 | Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects | COMPLETED | PHASE2/PHASE3 |
| NCT00056641 | Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients | COMPLETED | PHASE2 |
| NCT03223402 | Nevirapine + 3TC Based Maintenance Therapy for HIV Infection | COMPLETED | NA |
| NCT00144170 | Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2) | COMPLETED | PHASE3 |